Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3-Reference-Cited by-同舟云学术

Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3

Published:2022-11-10 Issue:22 Volume:65 Page:15433-15442
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Shvartsbart Artem¹^ORCID,Roach Jeremy J.²,Witten Michael R.³,Koblish Holly⁴,Harris Jennifer J.³,Covington Maryanne³,Hess Rodrigo³,Lin Luping⁵,Frascella Michelle³,Truong Lisa³,Leffet Lynn³,Conlen Patricia³,Beshad Elham²,Klabe Ron³,Katiyar Kamna³,Kaldon Laura³,Young-Sciame Ruth³,He Xin³,Petusky Susan³,Chen Kwang-Jong³,Horsey April³,Lei Hsiang-Ting³,Epling Leslie B.³,Deller Marc C.³,Vechorkin Oleg³,Yao Wenqing⁶

Affiliation:

1. Prelude Therapeutics, Wilmington, Delaware 19803, United States

2. Proteovant Therapeutics, King of Prussia, Pennsylvania 19406, United States

3. Incyte Corporation, Wilmington, Delaware 19803, United States

4. Ikena Oncology, Boston, Massachusetts 02210, United States

5. WuXi AppTec, Philadelphia, Pennsylvania 19112, United States

6. Synnovation Therapeutics, Wilmington, Delaware 19803, United States

Funder

Incyte Research Institute

Publisher

American Chemical Society (ACS)

Subject